Reply to "Predictable Superiority of Everolimus-Eluting Stent Over Paclitaxel-Eluting Balloon in Patients with In-Stent Restenosis"

Am J Cardiol. 2017 Aug 1;120(3):e3. doi: 10.1016/j.amjcard.2016.04.285. Epub 2016 May 6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Coronary Restenosis*
  • Drug-Eluting Stents*
  • Everolimus
  • Humans
  • Paclitaxel
  • Stents

Substances

  • Everolimus
  • Paclitaxel